<DOC>
	<DOCNO>NCT00071266</DOCNO>
	<brief_summary>The purpose study compare dose response safety Niacin ER/Lovastatin , Niaspan® Lovastatin , subject leg pain cause narrowing leg artery . At least 870 subject , leg pain cause narrowing leg artery take part study . Both Niaspan lovastatin ( Mevacor® ) approve United States Food Drug Administration ( FDA ) treat high cholesterol . Niacin ER/Lovastatin ( Advicor® ) , combination two drug , also approve FDA treat high cholesterol . The use Niacin ER/Lovastatin treat narrow leg artery relieve “ intermittent claudication ” ( leg pain cause narrowing artery leg ) consider investigational . An investigational use one approve FDA .</brief_summary>
	<brief_title>The Dose Response Niacin ER/Lovastatin Peak Walking Time ( PWT ) Patients With Intermittent Claudication - TROPIC</brief_title>
	<detailed_description>This Phase 3 , 32-week , double-blind , diet-intervention , randomize , parallel group , ten-arm , multi-center , multi-national , dose titration study evaluate safety efficacy NL patient intermittent claudication ( IC ) . The objective study evaluate safety efficacy NL patient IC . The primary efficacy analysis percent change baseline Peak Walking Time ( PWT ) calculate natural logarithm ratio time walk treadmill Week 32 Visit divide time walked baseline . Other efficacy measure include Claudication Onset Time ( COT ) percent change baseline Week 32 , change Ankle Brachial Index ( ABI ) , Quality Life ( QoL ) percent change Weeks 20 32 , low limb amputation , composite cardiovascular event ( MI , stroke , vascular death ) , coronary peripheral artery revascularizations . Safety variable include serum transaminase , routine chemistry parameter , hematology , adverse event . Pharmacokinetic analysis conduct well .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>INCLUSION CRITERIA : Men &amp; woman least 40 year age old . Women must pregnant breastfeed &amp; plan become pregnant breastfeed . History IC low extremity present least 6 month change symptoms previous 3 month prior screen . LDLC &lt; 160 mg/dL Triglycerides &lt; 800 . EXCLUSION CRITERIA : Severe neuropathy . Gross obesity ( BMI ≥ 40 ) . Presence critical limb ischemia define ischemic rest pain , gangrene , ulceration , pending amputation low extremity due severe PAD . Surgical intervention alleviate symptom claudication within 6 month endovascular intervention within 3 month . Documented CAD take cholesterolmodifying agent unable undergo washout judged Investigator due personal choice . Systolic blood pressure ≥160 mmHg &amp; /or diastolic blood pressure ≥95 mmHg . Presence clinically significant laboratory test abnormality liver renal function test , thyroid function HgbA1C . History alcohol abuse currently drink alcohol excess .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Intermittent Claudication</keyword>
	<keyword>Peripheral Arterial Disease</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Niacin</keyword>
	<keyword>Lovastatin</keyword>
	<keyword>PAD</keyword>
	<keyword>IC</keyword>
</DOC>